Alkermes Plc (NASDAQ:ALKS) SVP Michael J. Landine sold 25,000 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $33.05, for a total transaction of $826,250.00. Following the completion of the transaction, the senior vice president now owns 210,122 shares in the company, valued at $6,944,532.10. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of NASDAQ ALKS traded down $0.36 on Thursday, reaching $33.17. 643,396 shares of the company traded hands, compared to its average volume of 830,443. Alkermes Plc has a fifty-two week low of $27.54 and a fifty-two week high of $62.42. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.89 and a quick ratio of 2.63. The company has a market cap of $5.23 billion, a P/E ratio of -473.86 and a beta of 1.82.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Thursday, February 14th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.39. The firm had revenue of $316.00 million during the quarter, compared to the consensus estimate of $255.71 million. Alkermes had a negative net margin of 12.73% and a negative return on equity of 0.49%. The company’s revenue was up 14.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.31 EPS. As a group, equities research analysts anticipate that Alkermes Plc will post -0.41 EPS for the current year.

A number of research analysts have issued reports on the stock. Credit Suisse Group lowered shares of Alkermes from an “outperform” rating to an “underperform” rating and reduced their target price for the company from $47.00 to $31.00 in a report on Thursday, December 13th. TheStreet raised shares of Alkermes from a “d” rating to a “c-” rating in a research note on Tuesday, February 19th. Wolfe Research assumed coverage on shares of Alkermes in a research note on Friday, December 14th. They set an “underperform” rating for the company. BidaskClub downgraded shares of Alkermes from a “buy” rating to a “hold” rating in a research note on Friday, January 25th. Finally, Zacks Investment Research raised shares of Alkermes from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research note on Tuesday, January 29th. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $44.15.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in Alkermes by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 1,546,255 shares of the company’s stock worth $45,602,000 after purchasing an additional 76,621 shares in the last quarter. Norges Bank acquired a new stake in Alkermes during the 4th quarter worth approximately $31,645,000. Dimensional Fund Advisors LP increased its position in Alkermes by 58.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 361,457 shares of the company’s stock worth $10,664,000 after purchasing an additional 133,233 shares in the last quarter. Amalgamated Bank increased its position in Alkermes by 63.0% during the 4th quarter. Amalgamated Bank now owns 34,344 shares of the company’s stock worth $1,013,000 after purchasing an additional 13,277 shares in the last quarter. Finally, Macquarie Group Ltd. increased its position in Alkermes by 4.6% during the 4th quarter. Macquarie Group Ltd. now owns 107,609 shares of the company’s stock worth $3,176,000 after purchasing an additional 4,750 shares in the last quarter. 97.83% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2019/03/14/alkermes-plc-alks-svp-michael-j-landine-sells-25000-shares.html.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.

Read More: Tariff

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.